Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Immunology

Life After Treatment: Monitoring and Recovery

At a Glance

Following SCID treatment, children need careful long-term monitoring to ensure their new immune system functions properly. Doctors track T-cell and B-cell recovery, manage immunoglobulin therapy, and watch for late effects so children can safely return to normal activities like school.

The period following a transplant or gene therapy is a time of “watchful waiting” as your child’s body begins to build its new immune system. While the most intense part of the journey may be behind you, the months and years following treatment involve careful monitoring to ensure the “new” system is taking hold and functioning correctly [1][2].

Tracking Progress: Chimerism and Reconstitution

To see if the treatment is working, doctors track two main things: chimerism and immune reconstitution [3][1].

  • Chimerism: This is a test that measures what percentage of your child’s blood cells are “donor” cells versus their “own” cells [3][4].
    • Full Chimerism: 100% of the cells are from the donor.
    • Mixed Chimerism: A blend of donor and patient cells [3]. For many SCID patients, having even a small amount of donor cells in certain areas (like T-cells) is enough to provide protection [5][6].
  • Immune Reconstitution: This is the process of the new immune system actually “waking up.”
    • T-cells: These usually recover first, but it can take several months for them to reach healthy levels [7][8].
    • B-cells: These often take longer to recover. Whether or not your child’s B-cells work correctly often depends on the type of SCID they have and if they received chemotherapy (conditioning) before the transplant [8][1].

Immunoglobulin (IVIG/SCIG) Support

Many children will need immunoglobulin replacement therapy (IVIG or SCIG) for some time after transplant [9][10]. This treatment provides “borrowed” antibodies from healthy donors to protect your child while their own B-cells are still learning how to work [11].

  • Independence: Some children will eventually become “immunoglobulin independent,” meaning their own B-cells are making enough antibodies to protect them [9][1].
  • Lifelong Support: In some cases, if the B-cells do not fully recover, a child may need to stay on these infusions indefinitely. This is a common and manageable part of long-term SCID care [11][1].

Monitoring for “Late Effects”

As your child grows, their medical team will watch for “late effects”—health issues that can appear years after treatment [12].

  • Graft-versus-Host Disease (GVHD): This occurs when donor cells “attack” the recipient’s body. While more common in the first few months, a “chronic” version can sometimes appear later, affecting the skin, liver, or gut [7].
  • Endocrine and Growth: The chemotherapy used during “conditioning” can sometimes affect a child’s growth, thyroid function, or future fertility [12][13]. Regular checkups with an endocrinologist (hormone specialist) are a standard part of follow-up care [12].

The Road Back to Normalcy

The ultimate goal of SCID treatment is for your child to live a full, normal life.

  • School and Socializing: Once your child’s T-cell counts reach a certain level and they are no longer on heavy immune-suppressing drugs, they can eventually go to school, play sports, and attend birthday parties [14][15].
  • Vaccinations: Your child will eventually need to be “re-vaccinated” for everything they missed, but this is a slow process. Doctors usually start with “killed” (inactivated) vaccines and only consider “live” vaccines much later, once the immune system is proven to be strong [16][17].

While the “protective bubble” of early life may feel permanent right now, the vast majority of SCID survivors who are treated early go on to live healthy, active lives [15][14]. Return to the Home Page to review any steps you may have missed.

Common questions in this guide

What is chimerism testing after a SCID transplant?
Chimerism testing measures the percentage of your child's blood cells that come from the donor versus their own body. For many SCID patients, achieving full or even mixed chimerism shows that the new immune system is taking hold and providing protection.
How long will my child need immunoglobulin (IVIG) therapy after SCID treatment?
Many children require IVIG or SCIG therapy for months or years while their new B-cells learn to produce antibodies. Some children eventually become independent from these infusions, while others may need lifelong support depending on how well their B-cells recover.
What are the potential late effects of SCID treatments?
Late effects can include chronic Graft-versus-Host Disease (GVHD), which may affect the skin, liver, or gut. Additionally, the chemotherapy used before a transplant can sometimes impact a child's growth, thyroid function, or future fertility, requiring monitoring by a hormone specialist.
When can my child start receiving vaccinations after SCID treatment?
Re-vaccination is a slow process that begins only after your child's immune system shows strong recovery. Doctors typically start with inactivated (killed) vaccines and wait until the immune system is proven to be robust before considering any live vaccines.
When is it safe for a child treated for SCID to return to school and daycare?
Once your child's T-cell counts reach safe levels and they are no longer taking heavy immune-suppressing medications, they can usually return to normal activities. Your medical team will provide specific guidance on when their immune system is strong enough for public spaces.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my child's current chimerism percentage for both T-cells and B-cells?
  2. 2.What is the timeline for my child to begin re-vaccination with inactivated vaccines?
  3. 3.What specific signs of chronic Graft-versus-Host Disease (GVHD) should I look for at home?
  4. 4.Based on the conditioning my baby received, what specific long-term monitoring do we need for their growth and hormone levels?
  5. 5.When can we expect to try weaning off immunoglobulin (IVIG/SCIG) therapy?
  6. 6.When will it be safe for my child to go to public places like daycare or school?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Long-Term Health Outcome and Quality of Life Post-HSCT for IL7Rα-, Artemis-, RAG1- and RAG2-Deficient Severe Combined Immunodeficiency: a Single Center Report.

    Abd Hamid IJ, Slatter MA, McKendrick F, et al.

    Journal of clinical immunology 2018; (38(6)):727-732 doi:10.1007/s10875-018-0540-9.

    PMID: 30105620
  2. 2

    Late effects following hematopoietic cell transplantation for severe combined immunodeficiency: critical factors and therapeutic options.

    Eissa H, Cowan MJ, Heimall J

    Expert review of clinical immunology 2025; (21(1)):73-82 doi:10.1080/1744666X.2024.2402948.

    PMID: 39307944
  3. 3

    Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease.

    Scheiermann J, Künkele A, von Stackelberg A, et al.

    Frontiers in immunology 2023; (14()):1042650 doi:10.3389/fimmu.2023.1042650.

    PMID: 36875143
  4. 4

    Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.

    Nishimura A, Aoki Y, Ishiwata Y, et al.

    Journal of clinical immunology 2021; (41(5)):944-957 doi:10.1007/s10875-021-00966-z.

    PMID: 33527309
  5. 5

    Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.

    Kharfan-Dabaja MA, Kumar A, Ayala E, et al.

    Transplantation and cellular therapy 2021; (27(8)):642-649 doi:10.1016/j.jtct.2021.04.007.

    PMID: 34304802
  6. 6

    Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.

    Llaurador G, Nicoletti E, Prockop SE, et al.

    Transplantation and cellular therapy 2021; (27(9)):780.e1-780.e14 doi:10.1016/j.jtct.2021.05.020.

    PMID: 34082161
  7. 7

    Relevance of Recent Thymic Emigrants Following Allogeneic Hematopoietic Cell Transplantation for Pediatric Patients with Inborn Errors of Immunity.

    Drozdov D, Luo X, Marsh RA, et al.

    Transplantation and cellular therapy 2025; (31(4)):265.e1-265.e12 doi:10.1016/j.jtct.2025.02.003.

    PMID: 39923938
  8. 8

    Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution.

    Abdel-Azim H, Elshoury A, Mahadeo KM, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2017; (23(9)):1437-1446 doi:10.1016/j.bbmt.2017.05.005.

    PMID: 28495643
  9. 9

    Treatment of patients with immunodeficiency: Medication, gene therapy, and transplantation.

    Segundo GRS, Condino-Neto A

    Jornal de pediatria 2021; (97 Suppl 1()):S17-S23 doi:10.1016/j.jped.2020.10.005.

    PMID: 33181112
  10. 10

    Long-term outcome of hematopoietic stem cell transplantation for IL2RG/JAK3 SCID: a cohort report.

    Abd Hamid IJ, Slatter MA, McKendrick F, et al.

    Blood 2017; (129(15)):2198-2201 doi:10.1182/blood-2016-11-748616.

    PMID: 28209722
  11. 11

    B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.

    Miggelbrink AM, Logan BR, Buckley RH, et al.

    Blood 2018; (131(26)):2967-2977 doi:10.1182/blood-2017-10-809822.

    PMID: 29728406
  12. 12

    Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study.

    Eissa H, Thakar MS, Shah AJ, et al.

    The Journal of allergy and clinical immunology 2024; (153(1)):287-296 doi:10.1016/j.jaci.2023.09.027.

    PMID: 37793572
  13. 13

    Long Term Outcome and Immune Function After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency.

    Gennery AR, Lankester A,

    Frontiers in pediatrics 2019; (7()):381 doi:10.3389/fped.2019.00381.

    PMID: 31616648
  14. 14

    SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.

    Haddad E, Logan BR, Griffith LM, et al.

    Blood 2018; (132(17)):1737-1749 doi:10.1182/blood-2018-03-840702.

    PMID: 30154114
  15. 15

    Survival After Hematopoietic Stem Cell Transplantation in Severe Combined Immunodeficiency (SCID): A Worldwide Review of the Prognostic Variables.

    Goebel GA, de Assis CS, Cunha LAO, et al.

    Clinical reviews in allergy & immunology 2024; (66(2)):192-209 doi:10.1007/s12016-024-08993-5.

    PMID: 38689103
  16. 16

    Disseminated BCG infection revealing a severe combined immunodeficiency: A case report.

    Ben Belgacem H, Bouguila J, Tej A, et al.

    La Tunisie medicale 2022; (100(12)):881-886.

    PMID: 37551538
  17. 17

    BCG vaccination in children with severe combined immunodeficiency in a tertiary center: evaluation of complications and risks.

    Botaro MH, Maria E Silva J, Jamra SRA, et al.

    Jornal de pediatria 2025; (101(2)):224-230 doi:10.1016/j.jped.2024.09.008.

    PMID: 39681319

This page provides educational information about post-treatment recovery for SCID. Always consult your child's immunology team regarding their specific test results, immune reconstitution timeline, and long-term care plan.

Get notified when new evidence is published on Severe combined immunodeficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.